The development of controlled release-drug utilizing new quinolones for perlodontitis

点击翻译按钮获取中文摘要

This study was conducted to develop the new chemotherapeutic agents for periodontal diseases utilizing the local drug delivery system. Tosfloxacin (TFLX) was selected as anti-bacterial agent for this new agent because of its superior anti-bacterial activity against periodontopathic bacteria. We examined the controlled release activity of various matrices in our preliminary studies. Among them, non-hydrated gel based on potassium aluminum sulfate and HPMC2208 showed the best characteristics for its purpose. According to this result, test reagent was prepared by mixing 4% TFLX with gel based on potassium aluminum sulfate and HPMC2208. The persistence of TFLX releasing in the periodontal pockets using test reagent was also examined. In result, test reagent retained TFLX at the concentration of 10/γg/ml even 48 hours after application in the periodontal pocket. The safety of this reagent in application to periodontal pockets was also confirmed, because the side effects in medical and dental condition did not appear when this reagent was applied to periodontal pockets. Then, we evaluated the clinical effects of topical application of this reagent for pretreated periodontal pockets. The clinical parameters of the tested sites 2 weeks after the application, where the controlled release-drug was applied, was not significantly improved in comparison with the sites where non-treatment or matrix alone was applied. However, the high sensitive detectable method of Porphyromonas gingivalis (Pg) developed in this study showed that a tendency to decrease the proportion of Pg in the sites applied the test reagent in comparison with the other sites at 2 weeks after the application. These data show that the new reagent developed in this study has the possibility of becoming one of the unique chemotherapeutic agents for periodontitis with the feature of local drug delivery system.